Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma Journal Article
| Authors: | Casper, E. S.; Schwartz, G. K.; Johnson, B.; Kelsen, D. P. |
| Article Title: | Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma |
| Abstract: | We conducted a phase II evaluation of edatrexate in 17 previously untreated patients with advanced adenocarcinoma of the pancreas; 14 patients had at least one month of therapy. The initial dose was 80 mg/m2iv. Treatment was administered weekly for 5 weeks, then every other week. Toxicity was generally mild. The median WBC nadir was 5.4 (range 0.6-7.4)×103/μl, and the median platelet nadir was 164.0 (range 62.0-341.0)×103/μl. One patient died with sepsis and gastrointestinal bleeding associated with pancytopenia. Five patients had a mild rash. Nausea occurred in 6 patients, including 3 who had vomiting. In addition, 11 patients complained of vague malaise which seemed to begin within 24-48 hours after administration of edatrexate, and lasted for 2 to 3 days, resolving within 6 days of drug administration. Median survival was 85 days. Although 5 patients had stable disease, including one with relief of pain, no major responses were seen, excluding, with 95% confidence, a response rate in excess of 20%. © 1992 Kluwer Academic Publishers. |
| Keywords: | adult; cancer survival; clinical article; aged; advanced cancer; dose response; gastrointestinal hemorrhage; antineoplastic agents; pancreatic neoplasms; adenocarcinoma; pancreas; phase 2 clinical trial; blood toxicity; gastrointestinal symptom; drug administration schedule; drug effect; malaise; pancreas adenocarcinoma; sepsis; bile duct neoplasms; pancytopenia; phase ii; aminopterin; intravenous drug administration; middle age; edatrexate; human; male; female; priority journal; article; support, u.s. gov't, p.h.s. |
| Journal Title: | Investigational New Drugs |
| Volume: | 10 |
| Issue: | 4 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 1992-11-01 |
| Start Page: | 313 |
| End Page: | 316 |
| Language: | English |
| DOI: | 10.1007/bf00944187 |
| PUBMED: | 1487406 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work